Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers files Rx-to-OTC switch NDA for Vagistat-1; company reassigns ad agencies.

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL-MYERS SEEKING OTC STATUS FOR VAGISTAT-1, a single-dose yeast infection drug, the firm noted in its recently released annual report. The company has submitted a supplemental NDA for the product. Vagistat-1 was approved for OTC marketing in the U.K. in January 1994 ("The Tan Sheet" Feb. 21, 1994, p. 6), but has not yet been introduced there.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel